

1 **Serum levels of the novel adipokine isthmin-1 are associated with obesity in pubertal**
2 **boys**

3 Francisco Javier Ruiz-Ojeda^{1,2*}, Augusto Anguita-Ruiz^{1,2,3,4,5}, Maria C. Rico¹, Rosaura Leis^{5,6,7,8},
4 Gloria Bueno^{5,9,10}, Mercedes Gil-Campos^{4,11}, Ángel Gil^{1,2,3,5}, Concepción M Aguilera^{1,2,3,5*}

5

6 ¹ Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of
7 Granada, Spain

8 ² Instituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain

9 ³ Institute of Nutrition and Food Technology "José Mataix", Center of Biomedical Research,
10 University of Granada, Avda. del Conocimiento s/n. 18016 Armilla, Granada, Spain

11 ⁴ Barcelona Institute for Global Health, ISGlobal, 08003 Barcelona, Spain

12 ⁵ CIBEROBN, (Physiopathology of Obesity and Nutrition CB12/03/30038), Institute of Health
13 Carlos III (ISCIII), Madrid 28029, Spain

14 ⁶ Unit of Investigation in Human Nutrition, Growth and Development of Galicia (GALINUT),
15 University of Santiago de Compostela (USC), Santiago de Compostela, Spain

16 ⁷ Pediatric Nutrition Research Group. Institute of Sanitary Research of Santiago de Compostela
17 (IDIS). CHUS–USC. 15706 Santiago de Compostela, Spain

18 ⁸ Unit of Pediatric Gastroenterology, Hepatology and Nutrition. Pediatric Service. University
19 Clinical Hospital of Santiago (CHUS). 15706 Santiago de Compostela, Spain

20 ⁹ GENUUD Research group, University of Zaragoza, Institute of Sanitary Research of Aragón (IIS
21 Aragón), Zaragoza, Spain

22 ¹⁰ Agri-food Institute of Aragon (IA2), Zaragoza, Spain

23 ¹¹ Unit of Pediatric Endocrinology, University Clinical Hospital Lozano Blesa, 50009 Zaragoza,
24 Spain (G.B.) Metabolism and Investigation Unit, Reina Sofia University Hospital, Maimónides.
25 Institute of Biomedicine Research of Córdoba (IMIBIC), University of Córdoba, 14071 Córdoba,
26 Spain

27

28 *Corresponding Authors:

29 Francisco Javier Ruiz-Ojeda/Concepción Aguilera

30 Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of
31 Granada, Spain. Telephone: +34 626552847. E-mail: frujojeda@ugr.es/caguiler@ugr.es

32

33

34

35

36

37

38

39

40 **Abstract**

41 **Purpose:** The aims of this study were; 1) to evaluate if there is an association between the serum
42 levels of the novel insulin-like adipokine isthmin-1 (ISM1) and obesity-related phenotypes in a
43 population of Spanish children, 2) to investigate the plausible molecular alterations behind the
44 alteration of the serum levels of this protein in children with obesity.

45 **Methods:** The study population is a sub-cohort of the PUBMEP research project, consisting of a
46 cross-sectional population of 119 pubertal children with overweight (17 boys, 19 girls), obesity (20
47 boys, 25 girls) and normal weight (17 boys, 21 girls). All subjects were classified into experimental
48 groups according to their sex, obesity and insulin resistance (IR) status. They counted on
49 anthropometry, glucose, and lipid metabolism, inflammation and cardiovascular biomarkers as
50 well as ISM1 serum levels measured. This population was intended as a discovery population in
51 which to elucidate the relationship between obesity and ISM1 levels in children. Furthermore, the
52 study population had blood whole-genome DNA methylation allowing deepening into the obesity-
53 ISM1 molecular relationship.

54 **Results:** Higher serum levels of ISM1 were observed in boys with obesity when compared with
55 normal-weight ($P=0.004$), and overweight ($P=0.007$). ISM1 serum levels were positively
56 associated with BMI Z-score ($P=0.005$), and negatively with myeloperoxidase (MPO) ($p=0.043$)
57 in boys. Nevertheless, we did not find associations between ISM1 serum levels and metabolic
58 outcomes in girls, indicating a putative sexual dimorphism. DNA methylation levels in two-
59 enhancer-related CpG sites of ISM1 (cg03304641 and cg14269097) were associated with serum
60 levels of ISM1 in children.

61 **Discussion:** We report an unprecedented study that provides a major step forward showing that
62 ISM1 is robustly associated with obesity in pubertal boys, elucidating how this protein might be of
63 special relevance as a new biomarker of obesity in children.

64 **Keywords:** isthmin-1, obesity, children, puberty, epigenetics

65 **Implications and Contribution**

66 Study findings reveal differences in the circulating levels of the novel insulin-like adipokine ISM1
67 between pubertal children with obesity and normal-weight, and different associations with
68 metabolic traits, which may be further investigated to be used as a potential biomarker of obesity
69 in young populations.

70

71 Childhood obesity is increasing globally and total adiposity is the key driver of metabolic risk in
72 children and adolescent, which represent a strong risk factor for insulin resistance (IR) and future
73 type 2 diabetes (T2D) [1]. Puberty is a time of metabolic and hormonal changes, and it is
74 associated with a reduced insulin sensitivity that recovers at puberty completion in only some
75 children [2-4]. In growing children, adipocyte hypertrophy is associated with inflammation and
76 local and systemic IR, independently of BMI and fat mass, being adipose tissue essential to
77 maintain a functional metabolism [5]. However, the molecular mechanism of IR is still unknown,
78 particularly in children. This is in part because processes such as growth and puberty affect insulin
79 secretion and sensitivity [6]. Hence, understanding the molecular and biological processes
80 underlying metabolic changes (glucose and lipid regulation) during puberty, and identifying
81 pathways and biomarkers that might help to increase peripheral glucose uptake would be
82 beneficial to reduce the impact of obesity and to prevent T2D. A recent paper reported that the
83 protein isthmin-1 (ISM1) is secreted by mature adipocytes and triggers a signaling cascade similar
84 to that of insulin. The novel adipokine acts through a unidentified receptor tyrosine kinase and, at
85 pharmacological doses in mice, ISM1 ameliorates metabolic disturbances associated with T2D,
86 including hyperglycemia and liver steatosis [7, 8]. Here, we report that serum levels of the novel
87 insulin-like adipokine ISM1 is, indeed, associated with obesity in pubertal boys, but not in girls in
88 a well-characterized population of Spanish children under a cross-sectional design. Furthermore,
89 we identified DNA methylation in two-enhancer-related CpG sites of the ISM1 region (cg14269097
90 and cg14269097) associated with serum levels of ISM1 in children with obesity.

91 **Methods**

92 This study was conducted within the context of the multicenter PUBMEP study in Spain “Puberty
93 and metabolic risk in children with obesity”, previously published [9, 10]. Here, a sub-population
94 of 119 pubertal children (54 boys and 65 girls) from the whole PUBMEP cohort was selected for
95 analysis. A total of 38 were normal-weight (17 boys), 36 overweight (17 boys) and 45 children
96 with obesity (20 boys). The following characteristics were considered as exclusion criteria: birth
97 weight <2500 g; intake of any drug that could alter blood glucose, blood pressure or lipid
98 metabolism; not being able to comply with the study procedures and being participating or having
99 participated in the last three months in an investigation project. This study was conducted
100 according to the guidelines set out in the Declaration of Helsinki (Edinburgh 2000 revised), and
101 all procedures were approved by the Ethics and Research Committee of Galicia Autonomous
102 Community (2011/198 and 2016/522). Written consent was obtained from the parents of all the
103 children. Anthropometric measurements such as body weight (kg), height (cm), hip circumference

104 (cm) and waist circumference (WC) (cm) were measured using standardized procedures. BMI z-
105 score was calculated based on the Spanish reference standards published. Blood pressure was
106 measured three times for each individual by the same examiner using a mercury
107 sphygmomanometer and following international recommendations [11]. Measures of lipid and
108 glucose metabolism, hormones and classical biochemical parameters were performed at the
109 laboratories of each participating hospital following internationally accepted quality control
110 protocols. Blood samples were collected in overnight fasting conditions, centrifuged, and plasma
111 and serum were stored at -80°C . The presence of IR in children was defined according to the
112 HOMA insulin resistance (HOMA-IR) index. The cut-off points were obtained from a previously
113 well-described Spanish cohort composed of children and adolescents [12, 13]. The cut-off points
114 for IR were based on the 95th HOMA-IR percentile, considering sex (HOMA-IR ≥ 3.38 in boys and
115 HOMA-IR ≥ 3.90 in girls). These cut-off points have already been tested and validated as good
116 metabolic risk classifiers in our population according to the results from a previous PUBMEP
117 report [10]. Plasma adipokines, inflammation, and cardiovascular risk biomarkers (adiponectin,
118 leptin, resistin, tumor necrosis factor alpha (TNF- α), high-sensitivity CRP (hsCRP), interleukin
119 (IL)-6, IL-8, total plasminogen activator inhibitor-1 (PAI-1), P-selectin, myeloperoxidase (MPO),
120 monocyte chemoattractant protein 1 (MCP-1), soluble intercellular cell adhesion molecule-1
121 sICAM-1, and soluble vascular cell adhesion molecule-1 (sVCAM)) were analyzed in all samples
122 and time points using XMap technology (Luminex Corporation, Austin, TX) and human
123 monoclonal antibodies (Milliplex Map Kit; Millipore, Billerica, MA) as previously reported [10, 14].
124 Descriptive data are expressed as mean (standard deviation) or median [min-max] if not normally
125 distributed. One-way ANOVA, Kruskal-Wallis and the Welch test were employed to assess group
126 differences. DNA methylation analysis was carried out by using the Infinium MethylationEPIC
127 microarray using bead chip technology (Illumina, San Diego, CA, USA) as previously described
128 [10]. ISM1 protein levels were determined in serum using the Human SEQ515Hu for ISM 1
129 (Cloud-Clone Corp., USA), an enzyme-linked immune-absorbent assay kit according to the
130 manufacturers' instructions. The coefficient of variance was 4%. Two-way ANOVA and Tukey's
131 multiple comparisons test were employed to assess groups' differences in ISM1 levels between
132 boys and girls and normal-weight, overweight and obese children. Multiple linear regression
133 (MLR) analyses were applied for all continuous variables to study their association with ISM1
134 levels. In these analyses, origin, age, gender, pubertal stage, height, BMI Z-score, and insulin
135 were adjusted as confounders when necessary. A P-value <0.05 was considered as significant.
136 Given the number of analyzed outcomes, we considered false discovery rate (FDR) as in
137 Benjamini and Hochberg to correct for multiple hypothesis testing. MLRs were also applied for all

138 calculated deltas to study their correlation with the change in ISM1 levels. All described analyses
139 were performed in R environment version 3.6.0.

140 **Results**

141 General characteristics of the 119 children in this cross-sectional study are shown in
142 **Supplementary Table 1**. ISM1 serum levels according to obesity by sex are shown in **Fig. 1A**.
143 Higher ISM1 serum levels were observed in boys with obesity when compared with normal-weight
144 ($P = 0.0037$) and overweight ($P=0.0071$), non-adjusted. However, no changes were observed in
145 girls. When all subjects of the sample were compared together, we found higher levels in children
146 with obesity compared with those with normal weight ($P = 0.0413$) and with those overweight (P
147 $= 0.0102$). A trend to increase the ISM1 levels in boys with IR was observed, but no statistical
148 differences were shown between normal-weight non-IR, non-IR and IR children (**Fig. 1B**).

149 To elucidate the relationship between ISM1 and obesity, MLRs were further conducted in a wide
150 range of metabolic outcomes separated by sex (**Tables 1-2**) and properly adjusted by
151 confounders such as age, origin, height, BMI and IR when applicable. In boys, the strongest
152 association was found for BMI Z-score ($P=0.005$), but not in girls (**Fig. 2A and S1A**). MPO
153 ($P=0.043$) was negatively associated with ISM1 serum levels in boys. All of them were properly
154 adjusted for confounders (please, see **Table 1 and 2** legends), both in boys and girls. Surprisingly,
155 though both ISM1 and leptin levels are significantly higher in children with obesity, no significant
156 associations were identified with leptin neither in boys nor in girls (**Fig. 2B**).

157 Fifty-one methylation sites were selected from the Infinium Methylation EPIC microarray of which
158 two were annotated as promoter-associated CpGs (**Supplementary Table 2**). All the CpGs were
159 annotated as open sea. We found a positive significant association between the methylation
160 status of the probe cg03304641 and ISM1 serum levels in pubertal children ($P=0.0062$) (**Fig. 3A,**
161 **S2A and Supplementary Table 2**). However, for the probe cg14269097 there was a negative
162 association with ISM1 serum levels ($P=0.038$) (**Fig. 3B, S2B and Supplementary Table 2**).

163 **Discussion**

164 In the present work, we show higher serum levels of the novel insulin-like adipokine ISM1 in
165 pubertal children with obesity, with a strong association with BMI Z-score in boys. Moreover, ISM1
166 was also associated with MPO, an enzyme associated with IR and inflammation in individuals
167 with overweight [15]. These findings illustrate how this protein might be of special relevance as a
168 new biomarker of obesity in children.

169 In obesity, hypertrophic adipocytes and adipose tissue-resident immune cells accelerate a low-
170 grade and chronic, proinflammatory profile with altered secretion of adipokines and lipokines,

171 thereby exacerbating cardiometabolic disease [16]. In this context, the production and secretion
172 of adipokines and lipokines, which contribute to systemic energy metabolism by different
173 mechanisms, are dependent on the energy status of adipose tissue. Hence, further preclinical
174 and clinical studies exhibiting the activation or inhibiting the signaling of specific adipokines or
175 lipokines (e.g. by using adipokine-neutralizing antibodies) may be an approach suitable to treat
176 or prevent the development of metabolic disease. Nevertheless, efficacy and safety in humans
177 need to be confirmed [17]. ISM1 is a secreted protein, originally discovered in fetal brain
178 development and expressed in the brain, lung, vasculature, skin and immune cells [18]. ISM1 has
179 been recently identified in mouse and human adipocytes, regulating glucose uptake while
180 suppressing hepatic lipid synthesis, thus improving hyperglycemia and reducing lipid
181 accumulation in mouse models. Besides, circulating plasma levels of human ISM1 has been
182 detected at an average of 50 pg/mL and trend to positively correlate with BMI, but not with glucose
183 in female individuals [7]. Now, we reveal a relationship between circulating levels of ISM1 and
184 obesity is investigated in a pubertal population. The motivation for focusing on the identification
185 of new biomarkers in puberty lies in the fact that sexual maturation has been presented as a
186 significant metabolic risk period for children with obesity [4], and indeed, we previously described
187 the role of S100A4 in IR through a multi-omics approach in children, providing an interesting
188 knowledge into the plausible molecular mechanism underlying that association [10].
189 Here, in a pubertal sample of 119 children, we show how higher levels of ISM1 in children with
190 obesity compared to normal-weight and overweight, and a robust positive association between
191 ISM1 serum levels and BMI Z-score in boys, indicating a putative sexual dimorphism. However,
192 MPO was negatively associated with circulating levels of ISM1. Indeed, MPO is the most
193 abundant protein in human neutrophils, playing a major role in inflammation, oxidative stress,
194 lipoprotein oxidation, and atherosclerosis [15, 19]. Moreover, MPO deficient mice are resistant to
195 diet-induced obesity and IR, and inhibition of MPO activity in the neutrophils decreases diet-
196 induced IR in obese mice, and activation of MPO is associated with the development of obesity
197 and obesity-associated IR [20]. Group comparisons for ISM1 levels also revealed significant
198 results in boys, although no significant changes were observed when comparing extreme
199 experimental conditions in relation to IR (normal-weight vs. obese with IR). Jiang *et al.* (2021) [7]
200 determined that ISM1 signaling is dependent on PI3K and shares downstream phosphorylation
201 targets with insulin signaling, such as -AKT, p-AKT, p-ERK1/2 and p-S6. Outstandingly, ISM1
202 activates a PI3K-AKT signaling pathway independently of the insulin and insulin-like growth factor
203 1 receptors, being most likely to signal through another, yet to be identified, receptor tyrosine
204 kinase. We found a correlation with obesity but not with HOMA-IR in children, which would point

205 to the adipokine ISM1 with a direct role in obesity but not in the metabolic status derived from IR.
206 Remarkably, while the glucoregulatory function of the novel adipokine is shared with insulin, ISM1
207 also neutralizes lipid accumulation in the liver by inhibiting *de novo* lipogenesis, promoting protein
208 synthesis and preventing hepatic steatosis in a diet-induced fatty liver mouse model.
209 Nevertheless, in addition to a disturbed hepatic and postprandial lipoprotein metabolism,
210 enhanced triacylglycerol lipolysis in adipocytes and subsequent fatty acid flux to the liver are
211 major determinants of hepatic steatosis [21]. As insulin is a major anti-lipolytic hormone in
212 adipocytes, therefore, it is plausible that ISM1 signaling indirectly modulates hepatic lipid
213 accumulation by inhibiting fatty acid release from adipose tissue in mice (Heeren 2021a).
214 Additionally, in the paper of Jiang *et al.* (2021) [7], the therapeutic dosing of recombinant ISM1
215 improves glucose tolerance to the same degree as metformin, enhances diabetes in diet-induced
216 obese mice and ameliorates hepatic steatosis in a diet-induced fatty liver mouse model,
217 establishing that the recombinant *Ism1* and its derivatives may be explored for therapeutic
218 purposes and may offer certain advantages over current monotherapies. Nonetheless, the
219 observed higher circulating ISM1 levels in pubertal children suggest that maybe an ISM1
220 resistance is present, as administration of ISM1 into mice with established disease improves
221 glucose and lipid dysfunction in the diet-induced obesity. Additionally, we should consider that
222 pubertal children did not show hyperglycemia, which it might mask the observed effects of ISM1
223 in mice.

224 The strengths of our findings are the relatively high number of recruited children from different
225 centers in the country (Andalucia, Galicia and Aragón); the novelty of the recently described new
226 adipokine, which has not been reported elsewhere in humans, and the possibility to correlate with
227 several plasma adipokines, inflammation, and cardiovascular risk biomarkers in the subcohort.
228 Furthermore, the availability of DNA methylation analysis by using the Infinium MethylationEPIC
229 microarray using bead chip technology in all the children population allowed us to observe two-
230 enhancer related CpG sites of ISM1 (cg03304641 and cg14269097) associated with serum levels
231 of ISM1 in children. As a limitation, though ISM1 serum levels are associated with BMI Z-score,
232 we cannot distinguish the origin of the circulating levels simply because ISM1 is secreted by other
233 non-adipose cells, and a secondary validation population would be needed to confirm these
234 findings.

235 In conclusion, the circulating levels of the novel insulin-like adipokine ISM1 are significantly higher
236 in pubertal children with obesity, and strongly associated with BMI Z-score in boys. Furthermore,
237 we reveal two DNA methylations in two-enhancer-related CpG sites of the ISM1 region associated
238 with serum levels of the protein in children with obesity.

239

240 **Conflicts of interest:** The authors have no conflict of interests to disclose. No author received
241 any form of payment to produce this paper.

242 **Acknowledgements:** The authors would like to thank the children and parents who participated
243 in the study.

244 **Funding source:** This work was supported by the Plan Nacional de Investigación Científica,
245 Desarrollo e Innovación Tecnológica (I + D + I), Instituto de Salud Carlos III-Health Research
246 Funding (FONDOS FEDER) (PI051968, PI1102042 and PI1600871); Redes temáticas de
247 Investigación cooperativa RETIC (Red SAMID RD12/0026/0015) and the Mapfre Foundation.

248 **Author contributions:** CAG is the guarantor of this work. AG and CAG contributed to the study
249 concept of the cross-sectional study. FJRO, AAR and CAG design this study. RL, GB, MG, and
250 LM participated in the child recruitment and anthropometric measures (data acquisition). CAG
251 and AAR revised DNA extraction and methylation analyses. FJRO and MCR planned and
252 performed the ISM1 analysis in serum of the children. AAR and FJRO performed all data
253 analyses. AAR, FJRO and CAG took part in the interpretation of data. FJRO and CAG wrote the
254 manuscript. All authors took part in the critical revision of the manuscript. CAG, RL and GB
255 obtained funding. All authors approved the final version of the manuscript.

256 **Abbreviations:** IR, insulin resistance; WC, waist circumference; TNF- α , tumour necrosis factor
257 alpha; hsCRP, high-sensitivity CRP; IL, interleukin; PAI-1, total plasminogen activator inhibitor-1;
258 MPO, myeloperoxidase; MCP-1, monocyte chemoattractant protein 1; MMP-9, matrix
259 metalloproteinase-9; sICAM-1, soluble intercellular cell adhesion molecule-1; VCAM, soluble
260 vascular cell adhesion molecule-1; MLR, multiple linear regression; FDR, false discovery rate;
261 LME, linear mixed-effects; ISM1, isthmin-1; T2D, type 2 diabetes; MPO, myeloperoxidase.

262

263

264 **References**

- 265 1. Maffei, C. and A. Morandi, *Body composition and insulin resistance in children*. European
266 Journal of Clinical Nutrition, 2018. **72**(9): p. 1239-1245.
- 267 2. Kelsey, M.M., et al., *The Impact of Obesity On Insulin Sensitivity and Secretion During Pubertal*
268 *Progression: A Longitudinal Study*. The Journal of clinical endocrinology and metabolism, 2020.
269 **105**(5): p. e2061-e2068.
- 270 3. Reinehr, T., et al., *Strong effect of pubertal status on metabolic health in obese children: a*
271 *longitudinal study*. J Clin Endocrinol Metab, 2015. **100**(1): p. 301-8.

- 272 4. Reinehr, T. and C.L. Roth, *Is there a causal relationship between obesity and puberty?* Lancet
273 Child Adolesc Health, 2019. **3**(1): p. 44-54.
- 274 5. Luo, L. and M. Liu, *Adipose tissue in control of metabolism.* J Endocrinol, 2016. **231**(3): p. R77-
275 r99.
- 276 6. Hannon, T.S., J. Janosky, and S.A. Arslanian, *Longitudinal study of physiologic insulin resistance
277 and metabolic changes of puberty.* Pediatr Res, 2006. **60**(6): p. 759-63.
- 278 7. Jiang, Z., et al., *Isthmin-1 is an adipokine that promotes glucose uptake and improves glucose
279 tolerance and hepatic steatosis.* Cell Metab, 2021. **33**(9): p. 1836-1852.e11.
- 280 8. Heeren, J. and L. Scheja, *Isthmin 1 - a novel insulin-like adipokine.* Nat Rev Endocrinol, 2021.
281 **17**(12): p. 709-710.
- 282 9. Pires, L.V., et al., *The Vitamin D Decrease in Children with Obesity Is Associated with the
283 Development of Insulin Resistance during Puberty: The PUBMEP Study.* Nutrients, 2021. **13**(12).
- 284 10. Anguita-Ruiz, A., et al., *The protein S100A4 as a novel marker of insulin resistance in prepubertal
285 and pubertal children with obesity.* Metabolism, 2020. **105**: p. 154187.
- 286 11. McCrindle, B.W., *Assessment and management of hypertension in children and adolescents.* Nat
287 Rev Cardiol, 2010. **7**(3): p. 155-63.
- 288 12. Anguita-Ruiz, A., et al., *X chromosome genetic data in a Spanish children cohort, dataset
289 description and analysis pipeline.* Sci Data, 2019. **6**(1): p. 130.
- 290 13. Rupérez, A.I., et al., *Cardiovascular risk biomarkers and metabolically unhealthy status in
291 prepubertal children: Comparison of definitions.* Nutr Metab Cardiovasc Dis, 2018. **28**(5): p. 524-
292 530.
- 293 14. Ruiz-Ojeda, F.J., et al., *Effects of X-chromosome Tenomodulin Genetic Variants on Obesity in a
294 Children's Cohort and Implications of the Gene in Adipocyte Metabolism.* Sci Rep, 2019. **9**(1): p.
295 3979.
- 296 15. Gómez García, A., et al., *Myeloperoxidase is associated with insulin resistance and inflammation
297 in overweight subjects with first-degree relatives with type 2 diabetes mellitus.* Diabetes Metab J,
298 2015. **39**(1): p. 59-65.
- 299 16. Thomas, D. and C. Apovian, *Macrophage functions in lean and obese adipose tissue.*
300 Metabolism: clinical and experimental, 2017. **72**: p. 120-143.
- 301 17. Scheja, L. and J. Heeren, *The endocrine function of adipose tissues in health and cardiometabolic
302 disease.* Nat Rev Endocrinol, 2019. **15**(9): p. 507-524.
- 303 18. OsÓRio, L., X. Wu, and z. zhou, *Distinct spatiotemporal expression of ISM1 during mouse and
304 chick development.* Cell Cycle, 2014. **13**(10): p. 1571-1582.
- 305 19. Shao, B., S. Pennathur, and J.W. Heinecke, *Myeloperoxidase targets apolipoprotein A-I, the
306 major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic
307 lesions.* The Journal of biological chemistry, 2012. **287**(9): p. 6375-6386.
- 308 20. Wang, Q., et al., *Myeloperoxidase deletion prevents high-fat diet-induced obesity and insulin
309 resistance.* Diabetes, 2014. **63**(12): p. 4172-4185.
- 310 21. Heeren, J. and L. Scheja, *Metabolic-associated fatty liver disease and lipoprotein metabolism.*
311 Mol Metab, 2021. **50**: p. 101238.

312

313

314

315

316 **Table 1.** Association between the change in ISM1 serum levels and the change in metabolic
 317 outcomes in boys in the cross-sectional population (PUBMEP study).

Outcome	Beta	SE	CI.LOW	CI.HIGH	T-value	P-Value	FDR
BMI Z-score	0.356742	0.018365	0.017981	0.089973	2.939048	0.005009333*	0.1302427
MPO (µg/L)	-0.34989	2.845957	-11.495421	-0.339269	-2.079211	0.043596686*	0.4932982
SBP	0.262452	0.2514465	-0.04712895	0.9385412	1.772,569	0.08292251	0.4932982
AST (U/L)	0.273129	0.066067	-0.017778	0.241207	1.690916	0.097474922	0.4932982
ALT (U/L)	0.235236	0.113399	-0.033886	0.410636	1.661178	0.103196554	0.4932982
HsCRP (mg/L)	0.234346	0.348906	-0.128352	1.239357	1.592128	0.118205328	0.4932982
TAG (mg/dL)	0.232391	0.404079	-0.173903	1.410089	1.529632	0.132811041	0.4932982
Resistin (µg/L)	0.223976	0.104071	-0.057597	0.350361	1.406563	0.165998677	0.5394957
sICAM1 (mg/L)	-0.208464	0.009806	-0.031567	0.006874	-1.259028	0.214108936	0.6185369
GGT (U/L)	0.190581	0.104644	-0.081142	0.329061	1.184585	0.242137353	0.6295571
DBP	0.1500147	0.1634918	-0.1569578	0.48393	0.9999652	0.3225587	0.6671418
MCP1 (ng/L)	0.162466	0.694272	-0.676507	2.045038	0.985587	0.329277816	0.6671418
TNFα (ng/L)	0.14881	0.012211	-0.012852	0.035016	0.907526	0.368662495	0.6671418
Leptin (µg/L)	0.079798	0.057139	-0.06128	0.162704	0.887529	0.379220108	0.6671418
IL6 (ng/L)	-0.18923	0.788794	-2.241604	0.850468	-0.881812	0.384889528	0.6671418
QUICKI	0.122802	0.000445	-0.00051	0.001233	0.813133	0.420075148	0.6826221
tPAI1 (µg/L)	-0.082656	0.165824	-0.427502	0.222527	-0.618051	0.539463347	0.7869461
P Selectine (µg/L)	-0.09031	0.292972	-0.752906	0.395543	-0.609894	0.544808842	0.7869461
HDL-c (mg/dL)	-0.054999	0.162272	-0.382981	0.253125	-0.400119	0.690881956	0.8600189
Hip Circumference (cm)	-0.026917	0.09899	-0.229915	0.158124	-0.362617	0.718483164	0.8600189
IL8 (ng/L)	-0.056542	0.087295	-0.200509	0.141689	-0.336899	0.737662007	0.8600189
Insulin (mU/L)	-0.044402	0.117725	-0.266814	0.194668	-0.306415	0.760587143	0.8600189
HOMA-IR	-0.045483	0.026985	-0.061153	0.04463	-0.306152	0.760785993	0.8600189
Adiponectin (mg/L)	0.021981	0.103484	-0.186343	0.219314	0.159307	0.874095447	0.9469367
Glucose (mg/dL)	-0.001604	0.112144	-0.221027	0.218578	-0.010919	0.99133255	0.9913325

318
 319 Multiple regression analyses with the change in ISM1 serum levels as independent variable.
 320 Models were adjusted for the change in BMI Z-Score, the origin, and the pubertal stage reached.
 321 When the dependent variable was the change in the BMI Z-Score, we replaced the BMI
 322 confounder with the change in Insulin levels. The change in Height was further included in models
 323 when the dependent variable was change in Blood pressure. Abbreviations: SE, standard error;
 324 CI, confidence interval; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMI,
 325 body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood
 326 pressure; HOMA-IR, homeostasis model assessment for insulin resistance; QUICKI, quantitative
 327 insulin sensitivity check index; TAG, triglycerides; HDL-c, high-density lipoproteins-cholesterol;;
 328 hsCRP, high-sensitivity CRP; MCP-1, monocyte chemoattractant protein 1; GGT,
 329 Gammaglutamyltransferase; TNF-α, tumour necrosis factor alpha; TSH, thyroid-stimulating
 330 hormone; IL, interleukin; PAI-1, plasminogen activator inhibitor-1; MPO, myeloperoxidase;
 331 sICAM, soluble intercellular cell adhesion molecule-1. *P<0.05.

332
 333 **Table 2.** Association between the change in ISM1 serum levels and the change in metabolic
 334 outcomes in girls in the cross-sectional population (PUBMEP study).

Outcome	Beta	SE	CI.LOW	CI.HIGH	T-value	P-Value	FDR
HsCRP (mg/L)	-0.212532	0.275906	-0.993822	0.087729	-1.642031	0.10618814	0.9518221
tPAI1 (µg/L)	-0.203555	0.222168	-0.796221	0.074676	-1.623874	0.109825622	0.9518221
AST (U/L)	-0.161062	0.089849	-0.2849	0.067309	-1.210869	0.230856581	0.9591424
BMI Z-score	0.131089	0.024629	-0.02142	0.075127	1.090312	0.280008946	0.9591424
Adiponectin (mg/L)	-0.14196	0.115312	-0.350002	0.102022	-1.075251	0.286714995	0.9591424
ALT (U/L)	-0.122581	0.084927	-0.254045	0.07887	-1.031329	0.306668253	0.9591424
GGT (U/L)	-0.122033	0.068911	-0.199177	0.070953	-0.930365	0.35603822	0.9591424
QUICKI	-0.091113	0.00047	-0.001278	0.000563	-0.760771	0.449823868	0.9591424
HDL-c (mg/dL)	0.094496	0.228087	-0.278695	0.615407	0.738122	0.463416645	0.9591424
HOMA-IR	0.087244	0.034593	-0.042877	0.092727	0.720527	0.474046011	0.9591424

Insulin (mU/L)	0.075117	0.144802	-0.191328	0.376296	0.638694	0.525493807	0.9591424
Resistin (µg/L)	0.088929	0.20056	-0.267462	0.518732	0.626421	0.533496578	0.9591424
DBP	0.1065075	0.1772502	-0.2105193	0.4843014	0.772304	0.4433014	0.9591424
MPO (µg/L)	0.072895	2.284379	-3.32945	5.625316	0.502514	0.617556761	0.9591424
IL6 (ng/L)	0.076885	0.679751	-1.022602	1.642022	0.455622	0.651008589	0.9591424
TNFα (ng/L)	-0.05857	0.014978	-0.035842	0.022873	-0.432909	0.666686377	0.9591424
Glucose (mg/dL)	0.048341	0.153445	-0.247778	0.353727	0.345234	0.731167604	0.9591424
sICAM1 (mg/L)	-0.037412	0.005192	-0.011521	0.008831	-0.258988	0.796561463	0.9591424
Leptin (µg/L)	-0.027564	0.119642	-0.264583	0.204416	-0.251446	0.802358281	0.9591424
SBP	0.04020589	0.174974	-0.3043049	0.4120564	0.2948135	0.7692668	0.9591424
TAG (mg/dL)	0.018997	0.597412	-1.083729	1.258128	0.145962	0.884457754	0.9591424
IL8 (ng/L)	-0.020783	0.07327	-0.154252	0.132967	-0.145253	0.885014516	0.9591424
Hip Circumference (cm)	-0.004426	0.094848	-0.193113	0.178692	-0.076024	0.939666438	0.9591424
MCP1 (ng/L)	-0.008154	0.724891	-1.461766	1.379808	-0.056531	0.955113059	0.9591424
P Selectine (µg/L)	-0.006652	0.221513	-0.445564	0.422768	-0.051456	0.959142396	0.9591424

335

336 Multiple regression analyses with the change in ISM1 serum levels as independent variable.
 337 Models were adjusted for the change in BMI Z-Score, the origin, and the pubertal stage reached.
 338 When the dependent variable was the change in the BMI Z-Score, we replaced the BMI
 339 confounder with the change in Insulin levels. The change in Height was further included in models
 340 when the dependent variable was change in Blood pressure. Abbreviations: SE, standard error;
 341 CI, confidence interval; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMI,
 342 body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood
 343 pressure; HOMA-IR, homeostasis model assessment for insulin resistance; QUICKI, quantitative
 344 insulin sensitivity check index; TAG, triacylglycerols; HDL-c, high-density lipoproteins-cholesterol;
 345 hsCRP, high-sensitivity CRP; MCP-1, monocyte chemoattractant protein 1; GGT,
 346 Gammaglutamyltransferase; TNF-α, tumour necrosis factor alpha; TSH, thyroid-stimulating
 347 hormone; IL, interleukin; PAI-1, plasminogen activator inhibitor-1; MPO, myeloperoxidase;
 348 sICAM, soluble intercellular cell adhesion molecule-1. *P<0.05.

349 Figure legend

350 **Figure 1.** Group comparisons for ISM1 serum levels (ng/mL) in the pubertal population of 119
 351 children. **A)** Comparison between normal-weight, overweight and obese. **B)** Comparison between
 352 normal-weight non-IR, non-IR and IR in children. The two-way ANOVA, Tukey's multiple
 353 comparisons test was employed to assess group differences in ISM1 levels according to standard
 354 statistical assumptions. *P<0.05

355 **Figure 2.** Multiple linear regressions analyses between the change in ISM1 serum levels (ng/mL)
 356 and the changes in BMI Z-score and leptin (µg/L) in the cross-sectional cohort. **A** reports the linear
 357 model with delta BMI Z-score as dependent variable, **B** refers to the model for delta leptin as
 358 dependent variable.

359 **Figure 3.** Multiple linear regressions analyses between the change in ISM1 DNA methylation
 360 status and ISM1 serum levels (ng/mL). **A** reports the linear model with delta ISM1 serum levels
 361 as dependent variable and cg03304641 as independent variable. **B** refers the linear model with
 362 delta ISM1 serum levels as dependent variable and cg14269097 as independent variable.


363 **Supplementary Figures**

364 **Figure S1 related to Figure 2.** Multiple linear regressions were employed with M values as
365 independent variables and each outcome as the dependent variable. Models were adjusted for
366 confounders when necessary. Because percentage methylation is easily interpretable, beta
367 values were employed for the graphical representation of results. **A** refers to BMI Z-score as
368 dependent variable.

369 **Figure S2 related to Figure 3.** Cross-sectional associations between ISM1DNAmethylation
370 status and ISM1 serum levels (ng/mL). Multiple linear regressions were employed with M values
371 as independent variables and each outcome as the dependent variable. Models were adjusted
372 for confounders when necessary. Because percentage methylation is easily interpretable, beta
373 values were employed for the graphical representation of results.

Figure 1

A



B




Figure 2





Figure S1 related to Fig. 2

A

Boys

$t_{\text{student}}(52)=3.37, p=0.001, \hat{r}_{\text{pearson}}=0.42, \text{CI}_{95\%}[0.18,0.62], n=54$



Girls

$t_{\text{student}}(62)=1.29, p=0.201, \hat{r}_{\text{pearson}}=0.16, \text{CI}_{95\%}[-0.09,0.39], n=64$





Figure 3

A

Adj R2 = 0.23393 Intercept = -17.588 Slope = 3.2995
P = 0.0062655



B

Adj R2 = 0.22329 Intercept = -7.1039 Slope = -3.665
P = 0.038699





Figure S2 related to Fig. 3


A

$t_{\text{student}}(236)=1.21, p=0.228, \hat{r}_{\text{pearson}}=-0.08, \text{CI}_{95\%}[-0.20,0.05], n=238$



B

$t_{\text{student}}(236)=-1.18, p=0.241, \hat{r}_{\text{pearson}}=-0.08, \text{CI}_{95\%}[-0.20,0.05], n=238$



1 **Supplementary table 1.** General characteristics, anthropometry, biochemical parameters, adipokines and cardiovascular/pro-
 2 inflammatory biomarkers in the cross-sectional cohort of 119 Spanish children.

	Normal-weight	Overweight	Obese	P-Value
Age	14.87 [11.22-17.59] NA=0 ^a	14.22 [9.74-16.85] NA=0 ^a	14.33 [9.72-18.07] NA=0 ^a	0.15170492
Sex	Girls=20; Boys=17 NA=0	Girls=19; Boys=17 NA=0	Girls=25; Boys=20 NA=0	0.97257376
Glucose (mg/dL)	85.11 (9.03) NA=0 ^a	85.33 (6.76) NA=0 ^a	85.2 (8.71) NA=0 ^a	0.78038444
TAG (mg/dL)	63.25 (27.5) NA=1 ^b	66.69 (31.29) NA=0 ^{ab}	85.64 (37.49) NA=1 ^a	0.00101011
HDLc (mg/dL)	56.5 [32-86] NA=1 ^a	47 [26-70] NA=0 ^b	43 [3-107] NA=1 ^b	2.92E-06
AST (U/L)	22.36 (3.82) NA=1 ^a	20.94 (6.27) NA=0 ^a	22 (5.64) NA=1 ^a	0.15850533
ALT (U/L)	13.62 (4.16) NA=0 ^b	16.58 (6.34) NA=0 ^{ab}	21.11 (8.61) NA=0 ^a	1.22E-05
GGT (U/L)	11 [6-27] NA=1 ^a	13 [1-27] NA=0 ^{ab}	15 [2-44] NA=1 ^b	0.00117436
Insulin (mU/L)	8.73 (3.52) NA=0 ^b	12.58 (6.13) NA=0 ^b	21.08 (11.52) NA=0 ^a	6.60E-09
HsCRP (mg/L)	0.63 [0.2-30.1] NA=2 ^a	1.78 [0.2-18.4] NA=2 ^b	4.38 [0.2-164.2] NA=0 ^b	2.89E-05
Waist Hip ratio	0.82 [0.54-1.38] NA=0 ^a	0.83 [0.74-1] NA=1 ^a	0.93 [0.75-2.11] NA=1 ^b	8.42E-06
WC Height ratio	0.43 (0.05) NA=0 ^c	0.52 (0.05) NA=1 ^b	0.61 (0.08) NA=1 ^a	1.47E-28
QUICKI	0.35 [0.32-0.44] NA=0 ^a	0.34 [0.29-0.39] NA=0 ^b	0.31 [0.28-0.42] NA=0 ^c	7.70E-08
DBP (mm Hg)	67.16 (12.49) NA=2 ^a	67.93 (8.11) NA=2 ^a	70.44 (11.51) NA=1 ^a	0.29095778
SBP (mm Hg)	105.77 (13.7) NA=2 ^b	111.07 (12.35) NA=2 ^{ab}	116.7 (15.42) NA=1 ^a	0.01356016
Glucose (mmol/L)	4.72 (0.5) NA=0 ^a	4.74 (0.38) NA=0 ^a	4.73 (0.48) NA=0 ^a	0.78038444
HOMA-IR	1.84 (0.78) NA=0 ^b	2.69 (1.44) NA=0 ^b	4.53 (2.71) NA=0 ^a	5.38E-08
Waist Circumference (cm ²)	70.15 (7.99) NA=0 ^c	83.08 (7.8) NA=1 ^b	99.43 (11.47) NA=1 ^a	2.44E-25
Hip Circumference (cm ²)	85.37 (9.44) NA=0 ^c	97.59 (7.96) NA=1 ^b	108.88 (10.51) NA=1 ^a	7.87E-18
BMI Z-score	-0.12 [-1.59-0.78] NA=0 ^a	1.51 [0.75-2.3] NA=0 ^b	2.9 [2.03-5.82] NA=0 ^c	2.89E-22
sICAM1 (mg/L)	0.07 [0.04-3.31] NA=0 ^a	0.1 [0.06-2.03] NA=0 ^b	0.1 [0.06-1.72] NA=0 ^b	0.00219134
MPO (µg/L)	23.5 [0.8-196.36] NA=8 ^a	33.63 [0.88-1077.71] NA=3 ^a	32.47 [0.2-744.47] NA=2 ^a	0.31811663
P Selectin (µg/L)	42.17 (12.27) NA=0 ^b	47.1 (15.59) NA=0 ^{ab}	56.13 (20.87) NA=1 ^a	0.00630924
Adiponectin (mg/L)	13.47 (8.58) NA=0 ^a	12.57 (7.62) NA=0 ^a	8.35 (5.26) NA=0 ^b	0.00722112
Resistin (µg/L)	18.12 [9.19-44.31] NA=0 ^a	18.97 [7.82-56.01] NA=0 ^a	21.18 [10.91-77.23] NA=0 ^a	0.07726358
tPAI1 (µg/L)	8.95 (9.75) NA=0 ^b	16.67 (11.35) NA=0 ^b	25.25 (14.54) NA=0 ^a	1.40E-06

IL6 (ng/L)	8.28 [0.16-173.01] NA=9 ^a	2.89 [0.03-223.84] NA=17 ^a	3.67 [0.12-178.99] NA=8 ^a	0.14984527
IL8 (ng/L)	2.58 [0.56-27.33] NA=0 ^a	2.01 [0.27-30.27] NA=0 ^a	2.29 [0.13-22.8] NA=0 ^a	0.37108233
MCP1 (ng/L)	110.82 (39.87) NA=0 ^a	100.26 (48.49) NA=0 ^a	107.32 (39.99) NA=0 ^a	0.55119851
TNF α (ng/L)	2.73 (0.76) NA=0 ^a	2.57 (1.02) NA=0 ^a	2.66 (0.78) NA=0 ^a	0.71217629
Leptin (ng/L)	3.93 [0.19-21.63] NA=0 ^a	10.7 [1.53-41.58] NA=0 ^b	14.64 [6.42-37.32] NA=0 ^c	2.87E-10
ISM1 (ng/mL)	12.36 [3.9-32.55] NA=0 ^a	13.79 [4.81-31.4] NA=0 ^a	16.77 [6.21-51.7] NA=0 ^a	0.06447697

3

4 Data are expressed as mean (standard deviation) or median [min-max] if not normally distributed. One-way ANOVA, Kruskal-Wallis
5 and the Welch test were employed to assess group differences. Distributions within the same row with unlike superscript letters were
6 significantly different ($p < 0.05$) according to Pairwise-t-tests, pairwise Mann–Whitney U-tests and Dunn tests. Childhood obesity was
7 defined according to Cole et al. (2000). Abbreviations: ALR, adiponectin leptin ratio; Apo B, apolipoprotein B; Apo A, apolipoprotein A;
8 BMI, body mass index; DBP, diastolic blood pressure; HC, hip circumference; HDL-c, high-density lipoproteins-cholesterol; HOMA-IR,
9 homeostasis model assessment for insulin resistance; hsCRP, high-sensitivity C reactive protein; IL, interleukin; IR, insulin resistance;
10 ISM1, isthmin-1; LDL-c, low-density lipoproteins-cholesterol; MCP-1, monocyte chemoattractant protein 1; MPO, myeloperoxidase;
11 OB, obesity; PAI-1, plasminogen activator inhibitor-1; QUICKI, quantitative insulin sensitivity check index; SBP, systolic blood pressure;
12 sICAM, soluble intercellular cell adhesion molecule-1; TAG, triacylglycerols; THS; Thyroid-Stimulating Hormone; TNF- α , tumour
13 necrosis factor alpha; WC, waist circumference. NA: non-available value.

14

15

16

17

18

19

20

21

22

23

24 **Supplementary table 2.** List of Mapped CpG sites in the ISM1 domain.

chr	pos	strand	CpG name	Probe_rs	Probe_maf	UCSC_Ref Gene_Group	DNase_Hypersensitivity_NAME	DNase_Hyper sensitivity_E vidence_Count	TFBS_NAME	TFBS_E vidence _Count	Methyl450 _Loci
chr20	13200939	+	cg25796439	NA	NA	TSS1500	chr20:13200665- 13201130	3			TRUE
chr20	13200992	+	cg21561970	NA	NA	TSS1500	chr20:13200665- 13201130	3			TRUE
chr20	13201650	+	cg15015034	NA	NA	TSS1500	chr20:13201440- 13201875	3			TRUE
chr20	13201214	+	cg11155707	rs3590730 5	0,297039	TSS1500	chr20:13201165- 13201435	3			TRUE
chr20	13201655	+	cg03172651	NA	NA	TSS1500	chr20:13201440- 13201875	3			TRUE
chr20	13200982	+	cg26322248	NA	NA	TSS1500	chr20:13200665- 13201130	3			TRUE
chr20	13201225	+	cg03725761	rs3590730 5	0,297039	TSS1500	chr20:13201165- 13201435	3			TRUE
chr20	13201662	+	cg27427234	NA	NA	TSS1500	chr20:13201440- 13201875	3			TRUE
chr20	13202437	+	cg10378364	NA	NA	1stExon	chr20:13202025- 13202550	3			TRUE
chr20	13200944	+	cg14060111	NA	NA	TSS1500	chr20:13200665- 13201130	3			TRUE
chr20	13202476	-	cg04920227	NA	NA	1stExon	chr20:13202025- 13202550	3			TRUE
chr20	13280130	+	cg02962406	NA	NA	3'UTR			chr20:132794 40-13280456	3	TRUE
chr20	13200973	+	cg06262436	NA	NA	TSS1500	chr20:13200665- 13201130	3			TRUE
chr20	13201342	+	cg23504092	NA	NA	TSS1500	chr20:13201165- 13201435	3			TRUE
chr20	13280201	+	cg19727767	NA	NA	3'UTR			chr20:132794 40-13280456	3	TRUE
chr20	13201844	-	cg12741255	rs7133029 3	0,296533	TSS1500	chr20:13201440- 13201875	3			TRUE
chr20	13200954	+	cg12664209	NA	NA	TSS1500	chr20:13200665- 13201130	3			TRUE
chr20	13201328	+	cg15577927	NA	NA	TSS1500	chr20:13201165- 13201435	3			TRUE
chr20	13202222	+	cg20770339	NA	NA	TSS200	chr20:13202025- 13202550	3			TRUE
chr20	13200969	+	cg02145932	NA	NA	TSS1500	chr20:13200665- 13201130	3			TRUE
chr20	13201829	-	cg25178765	rs7133029 3	0,296533	TSS1500	chr20:13201440- 13201875	3			TRUE

chr20	13202225	+	cg20081364	NA	NA	TSS200	chr20:13202025-13202550	3		TRUE	
chr20	13201551	+	cg06567525	NA	NA	TSS1500	chr20:13201440-13201875	3		TRUE	
chr20	13200980	+	cg09491991	NA	NA	TSS1500	chr20:13200665-13201130	3		TRUE	
chr20	13200931	+	cg04432319	NA	NA	TSS1500	chr20:13200665-13201130	3		TRUE	
chr20	13253578	-	cg11466857	NA	NA	Body					
chr20	13246774	-	cg22470917	rs7269783	0,059433	Body	chr20:13246645-13246895	3			
chr20	13251901	-	cg04049812	NA	NA	Body	chr20:13251840-13252255	3			
chr20	13228392	+	cg01440309	NA	NA	Body	chr20:13227965-13228730	3			
chr20	13202489	-	cg06355010	NA	NA	1stExon	chr20:13202025-13202550	3		TRUE	
chr20	13203343	+	cg12235430	NA	NA	Body					
chr20	13226652	-	cg21903043	rs1404565 70	0,0133	Body					
chr20	13280181	+	cg16294620	NA	NA	3'UTR			chr20:132794 40-13280456	3	TRUE
chr20	13243701	-	cg02885188	NA	NA	Body	chr20:13243460-13243955	3			
chr20	13211902	+	cg14269097	NA	NA	Body	chr20:13211665-13211950	3			
chr20	13226121	-	cg18950540	NA	NA	Body	chr20:13226080-13226250	3			
chr20	13201670	+	cg03623378	NA	NA	TSS1500	chr20:13201440-13201875	3		TRUE	
chr20	13201353	+	cg19118558	NA	NA	TSS1500	chr20:13201165-13201435	3		TRUE	
chr20	13279847	+	cg25787377	NA	NA	Body			chr20:132794 40-13280456	3	TRUE
chr20	13279946	+	cg19647607	NA	NA	Body			chr20:132794 40-13280456	3	TRUE
chr20	13243555	-	cg24256058	NA	NA	Body	chr20:13243460-13243955	3			
chr20	13279761	+	cg20777315	NA	NA	Body			chr20:132794 40-13280456	3	TRUE
chr20	13277967	+	cg24488317	NA	NA	Body	chr20:13277725-13278235	3		TRUE	
chr20	13205832	+	cg25411902	NA	NA	Body					TRUE
chr20	13227047	+	cg03304641	rs1112843 24	0,035224	Body					
chr20	13261553	+	cg13735403	NA	NA	Body	chr20:13261540-13261770	3			
chr20	13201349	+	cg25384906	NA	NA	TSS1500	chr20:13201165-13201435	3		TRUE	

chr20	13201205	-	cg19938101	rs3450233 5	0,000455	TSS1500	chr20:13201165- 13201435	3	TRUE
chr20	13201216	+	cg25606624	rs3590730 5	0,297039	TSS1500	chr20:13201165- 13201435	3	TRUE
chr20	13201193	-	cg12448198	rs3450233 5	0,000455	TSS1500	chr20:13201165- 13201435	3	TRUE
chr20	13267421	+	cg09495909	NA	NA	Body	chr20:13267320- 13267535	3	